LOS ANGELES, Feb. 10, 2010 (GLOBE NEWSWIRE) -- EquityNet Research, an independent West Coast equity research firm, announced today that it has initiated coverage on Huifeng Bio-Pharmaceutical Technology, Inc. (OTCBB:HFGB).
A full copy of the report and disclosure requirements are available at EquityNet Research's Web site: www.equitynet.net.
Huifeng develops, produces and sells botanical extracts, active pharmaceutical ingredients (APIs) and pharmaceutical raw materials in mainland China and internationally, to the pharmaceutical, nutraceutical and food and beverage markets.
Randy Lewis, CFA, Founder and Senior Analyst with EquityNet who is covering the Company, stated, "Huifeng's founders, management team and directors draw on decades of experience in a variety of industries, as well as entrepreneurial business and financial management. The team is led by CEO, Mr. Jingan Wang, who has over fifteen years of experience in accounting and financial management area. Mr. Wang has served as CFO for various companies during his professional career and in 2004 was awarded "Entrepreneur of the Year" by the Xian Hi Tech Development.
"As consumers around the world attempt to deal with rising healthcare prices and the desire for healthier lifestyles, the Company has proven its ability to deliver quality products that are in high demand and for which it owns patents on efficient production methods," Mr. Lewis noted.
"The Chinese pharmaceutical market is expected to reach $68-78 billion by 2013 and rank 3rd in the world. According to Nutrition Business Journal, the total retail natural products market totaled approximately $101.8 billion in retail sales in calendar 2008."
About EquityNet Research
EquityNet Research was formed to provide the investing public with professional, independent, objective research on under-followed public companies. It does this by preparing detailed reports that highlight the key aspects of each company and its industry. EquityNet strictly maintains independence and objectivity according to the Standards of Professional Conduct of the CFA Institute (CFAI), and though is compensated for performing due diligence and creating reports, thus keeping its research free to the public, does not have extraneous relationships with its followed-companies nor has any present or future pecuniary benefit other than that disclosed for each company on its Web site. EquityNet was compensated $7,000 by Investor Relations Network for the due diligence, preparation, and any updates for one year, of the Huifeng report. EquityNet is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Price targets should be construed as fair-market-value (FMV) as of the date of any report, using industry-standard methodologies. Many factors can cause stock prices to deviate from FMV, including supply and demand issues, and general equity market conditions.